Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-prolyl cis-trans isomerase A-like 4F (PPIAL4F) is a predicted human protein and paralog of peptidyl-prolyl isomerase A (PPIA, cyclophilin A), but its function has not been experimentally verified. Based on sequence similarity, it is believed to belong to the cyclophilin family of peptidyl-prolyl cis-trans isomerases, which catalyze the cis-trans isomerization of proline residues in polypeptides and promote protein folding. However, PPIAL4F has been described in some databases as a pseudogene or as having uncertain protein-coding potential[5][7][9]. There is no known evidence that PPIAL4F is an active enzyme or therapeutically tractable target; it is not implicated in any specific biological function or disease, and no drug interactions or biomarker utility are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase A-like 4F (PPIAL4F).